Why Moderna Could Triple Its COVID Vaccine Sales Next Year
When Moderna (NASDAQ: MRNA) provided its fourth-quarter update in February, the biotech stated that it expected $18.4 billion in sales for its COVID-19 vaccine. However, that outlook was based on advanced purchase agreements in place at that time. Since then, Moderna has lined up more supply deals.
It won't be surprising if the company raises its sales projection to more than $20 billion when it announces first-quarter results Thursday. But there's a good reason to think that whatever its vaccine makes this year could be just the tip of the iceberg. Here's why Moderna just might be able to triple its COVID vaccine sales next year.
Image source: Getty Images.
Source Fool.com
